Balaxi Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
Balaxi Pharmaceuticals has been growing earnings at an average annual rate of 3%, while the Healthcare industry saw earnings growing at 23.2% annually. Revenues have been growing at an average rate of 21.5% per year. Balaxi Pharmaceuticals's return on equity is 16.5%, and it has net margins of 13.5%.
Key information
3.0%
Earnings growth rate
-0.5%
EPS growth rate
| Healthcare Industry Growth | 29.4% |
| Revenue growth rate | 21.5% |
| Return on equity | 16.5% |
| Net Margin | 13.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Balaxi Pharmaceuticals (NSE:BALAXI) Strong Profits May Be Masking Some Underlying Issues
Nov 13
These 4 Measures Indicate That Balaxi Pharmaceuticals (NSE:BALAXI) Is Using Debt Reasonably Well
Jul 30Balaxi Pharmaceuticals Limited's (NSE:BALAXI) Share Price Could Signal Some Risk
May 29Market Might Still Lack Some Conviction On Balaxi Pharmaceuticals Limited (NSE:BALAXI) Even After 38% Share Price Boost
Feb 10Balaxi Pharmaceuticals (NSE:BALAXI) Has A Pretty Healthy Balance Sheet
Feb 09Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?
Aug 08The Trend Of High Returns At Balaxi Pharmaceuticals (NSE:BALAXI) Has Us Very Interested
May 20A Look At The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)
Feb 03Calculating The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)
Sep 06Balaxi Pharmaceuticals (NSE:BALAXI) Knows How To Allocate Capital Effectively
Jun 03Is Weakness In Balaxi Pharmaceuticals Limited (NSE:BALAXI) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Mar 12Is Balaxi Pharmaceuticals Limited's(NSE:BALAXI) Recent Stock Performance Tethered To Its Strong Fundamentals?
Nov 27
Revenue & Expenses Breakdown
How Balaxi Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,636 | 356 | 741 | 0 |
| 30 Jun 24 | 2,410 | 454 | 663 | 0 |
| 31 Mar 24 | 2,413 | -24 | 657 | 0 |
| 31 Dec 23 | 2,621 | -52 | 605 | 0 |
| 30 Sep 23 | 2,879 | -106 | 623 | 0 |
| 30 Jun 23 | 3,196 | -95 | 688 | 0 |
| 31 Mar 23 | 3,364 | 460 | 727 | 0 |
| 31 Dec 22 | 3,449 | 506 | 751 | 0 |
| 30 Sep 22 | 3,200 | 545 | 627 | 0 |
| 30 Jun 22 | 3,038 | 511 | 466 | 0 |
| 31 Mar 22 | 2,794 | 477 | 312 | 0 |
| 31 Dec 21 | 2,416 | 433 | 209 | 0 |
| 30 Sep 21 | 2,457 | 421 | 184 | 0 |
| 30 Jun 21 | 2,373 | 401 | 177 | 0 |
| 31 Mar 21 | 2,313 | 381 | 161 | 0 |
| 31 Dec 20 | 1,939 | 312 | 73 | 0 |
| 30 Sep 20 | 1,411 | 228 | 56 | 0 |
| 30 Jun 20 | 938 | 138 | 36 | 0 |
| 31 Mar 20 | 456 | 61 | 46 | 0 |
| 31 Dec 19 | 416 | 53 | 18 | 0 |
| 30 Sep 19 | 342 | 40 | 17 | 0 |
| 30 Jun 19 | 230 | 31 | 13 | 0 |
| 31 Mar 19 | 140 | 20 | 10 | 0 |
| 31 Dec 18 | 79 | 11 | 6 | 0 |
| 30 Sep 18 | 15 | -3 | 3 | 0 |
| 30 Jun 18 | 0 | -8 | 2 | 0 |
| 31 Mar 18 | 0 | -8 | 2 | 0 |
| 31 Dec 17 | -6 | -12 | 1 | 0 |
| 30 Sep 17 | -6 | -11 | 1 | 0 |
| 30 Jun 17 | -6 | -8 | 1 | 0 |
| 31 Mar 17 | 0 | -2 | 1 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
| 30 Sep 16 | 0 | -1 | 1 | 0 |
| 30 Jun 16 | 0 | -1 | 1 | 0 |
| 31 Mar 16 | 0 | -1 | 1 | 0 |
| 31 Dec 15 | 2 | -1 | 1 | 0 |
| 31 Mar 15 | 2 | 1 | 0 | 0 |
| 31 Mar 14 | 2 | 1 | 0 | 0 |
Quality Earnings: BALAXI has a high level of non-cash earnings.
Growing Profit Margin: BALAXI became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BALAXI's earnings have grown by 3% per year over the past 5 years.
Accelerating Growth: BALAXI has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BALAXI has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (33.2%).
Return on Equity
High ROE: BALAXI's Return on Equity (16.5%) is considered low.